A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Exclusion Criteria

• •Evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal, respiratory, endocrine, hematologic, neurologic, or psychiatric disease or abnormalities or a known history of any gastrointestinal surgery that could impact the pharmacokinetics (PK)of the study drug.
• •Agents associated with thrombotic events (including oral contraceptives) must be discontinued within 30 days of the first study drug administration.
• •Evidence of organ dysfunction or any clinically significant deviation from normal in their medical history, e.g., history of splenectomy.
• •History of venous or arterial thrombotic disease or other hypercoaguable state.
• •Hemoglobin level less than 11.5 g/dL for females and 13.5g /dL for males